TD Cowen analyst Yaron Werber has maintained their bullish stance on VOR stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yaron Werber has given his Buy rating due to a combination of factors, including solid clinical execution and a strengthened balance sheet that together support Vor Biopharma’s long‑term growth prospects. He points to the rapid initiation and first patient dosing in the global Phase 3 UPSTREAM Sjögren’s trial, built on prior statistically significant and clinically meaningful Phase 3 data from China, as validation of telitacicept’s differentiated dual BAFF/APRIL mechanism and its potential in a difficult autoimmune indication.
He also highlights the accelerated timeline for global Phase 3 UPSTREAM MG topline data in generalized myasthenia gravis, now expected in the first half of 2027, which enhances visibility on upcoming value‑creating catalysts. In addition, the recently completed $75 million private placement, contributing to a total cash position of about $530 million and extending runway into early 2029, meaningfully reduces near‑term financing overhang while the two pivotal global programs advance, underpinning his constructive stance on the shares.
Werber covers the Healthcare sector, focusing on stocks such as Amgen, Ionis Pharmaceuticals, and Ascendis Pharma. According to TipRanks, Werber has an average return of 23.3% and a 58.75% success rate on recommended stocks.
In another report released yesterday, Jefferies also initiated coverage with a Buy rating on the stock with a $50.00 price target.